Ground Swell Capital LLC bought a new position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 22,864 shares of the company’s stock, valued at approximately $49,000. Ground Swell Capital LLC owned 0.20% of bioAffinity Technologies at the end of the most recent quarter.
Wall Street Analyst Weigh In
Separately, Maxim Group started coverage on bioAffinity Technologies in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $6.00 price target on the stock.
Check Out Our Latest Analysis on BIAF
bioAffinity Technologies Stock Performance
bioAffinity Technologies (NASDAQ:BIAF – Get Free Report) last issued its earnings results on Wednesday, August 14th. The company reported ($0.19) earnings per share (EPS) for the quarter. The company had revenue of $2.40 million during the quarter. bioAffinity Technologies had a negative net margin of 120.76% and a negative return on equity of 172.06%.
About bioAffinity Technologies
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.
See Also
- Five stocks we like better than bioAffinity Technologies
- What is an Earnings Surprise?
- Don’t Overlook Unity: Why This Stock Could Be Ready to Soar
- What is the Nikkei 225 index?
- Verint Systems’ AI Bots Revolutionize Customer Service Efficiency
- Quiet Period Expirations Explained
- Unlock Private Equity Opportunities for All Investors
Want to see what other hedge funds are holding BIAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bioAffinity Technologies, Inc. (NASDAQ:BIAF – Free Report).
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.